Ajanta Pharma Posed To Deliver Double Digit Growth: Systematix Reiterates ‘Buy’ Post Strong Q1 Results
Ajanta Pharma Ltd.’s Q1 FY26 revenue surged 13.8% YoY and 11.3% QoQ, driven by strong growth in North America and India branded formulation. Systematix maintains a ‘Buy’ rating with a target price of Rs 3,293.